Cite
MLA Citation
Kevin Harrington et al.. “408 Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors.” Journal for immunotherapy of cancer, vol. 8, n.d., p. A248. http://access.bl.uk/ark:/81055/vdc_100144715117.0x000003